News
EXAS
101.43
-0.18%
-0.18
LABU: The Risks And Rewards Of A Leveraged Biotechnology ETF
Seeking Alpha · 1d ago
Weekly Report: what happened at EXAS last week (1208-1212)?
Weekly Report · 3d ago
Quest Diagnostics Stock: Is DGX Outperforming the Healthcare Sector?
Barchart · 3d ago
November $10B+ M&A Deals Set Q4 Up To Outpace Prior Quarter
Seeking Alpha · 6d ago
Exact Sciences Unveils Promising Oncodetect MRD Test Results in Early Triple-Negative Breast Cancer Study
Reuters · 12/11 22:30
EXACT SCIENCES, THE NSABP FOUNDATION, AND THE GERMAN BREAST GROUP PRESENT RESULTS FOR THE ONCODETECT® MRD TEST IN EARLY TRIPLE-NEGATIVE BREAST CANCER AT SABCS
Reuters · 12/11 22:30
XBI, EXAS, RVMD, RNA: ETF Outflow Alert
NASDAQ · 12/11 17:53
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS
Barchart · 12/11 16:30
Illumina Partners with MyOme to Advance AI-Driven Genomic Health Solutions
Reuters · 12/11 14:15
Weekly Report: what happened at EXAS last week (1201-1205)?
Weekly Report · 12/08 09:48
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?
Benzinga · 12/05 18:33
3 Overrated Stocks That Concern Us
Barchart · 12/04 04:56
Top 2 Health Care Stocks You May Want To Dump This Month
Benzinga · 12/02 14:01
$100 Invested In Exact Sciences 15 Years Ago Would Be Worth This Much Today
Benzinga · 12/01 15:45
Cathie Wood's Ark Invest weekly recap: Boosts AI and Crypto Bets, Trims Palantir, GitLab, and AMD
Seeking Alpha · 12/01 11:04
Weekly Report: what happened at EXAS last week (1124-1128)?
Weekly Report · 12/01 09:46
Cathie Wood Marks Black Friday with Bitcoin ETF Buy and GitLab Stock Sell-Off
TipRanks · 11/29 14:54
Exact Sciences, Regeneron, Marvell, JFrog, Jazz: Trending by Analysts
TipRanks · 11/29 09:00
Exact Sciences downgraded to Hold from Buy at Stifel
TipRanks · 11/28 21:00
Catalyst Watch: Holiday shopping data, Amazon event, and Salesforce earnings
Seeking Alpha · 11/28 18:30
More
Webull provides a variety of real-time EXAS stock news. You can receive the latest news about Exact Sciences Corp through multiple platforms. This information may help you make smarter investment decisions.
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.